Mild Psoriasis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Mild Psoriasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Mild Psoriasis - Pipeline Review, H2 2014', provides an overview of the Mild Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mild Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mild Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mild Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mild Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mild Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mild Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mild Psoriasis Overview 6
Therapeutics Development 7
Pipeline Products for Mild Psoriasis - Overview 7
Pipeline Products for Mild Psoriasis - Comparative Analysis 8
Mild Psoriasis - Therapeutics under Development by Companies 9
Mild Psoriasis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Mild Psoriasis - Products under Development by Companies 12
Mild Psoriasis - Companies Involved in Therapeutics Development 13
Avexxin AS 13
Convoy Therapeutics, Inc. 14
Delenex Therapeutics AG 15
GlycoMar Limited 16
OPKO Health, Inc. 17
Soligenix, Inc. 18
UCB S.A. 19
Mild Psoriasis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AKP-11 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AVX-001 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cyclosporine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DLX-105 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DLX-3003 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GLY-2028 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
lunacalcipol - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SGX-301 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
UCB-5857 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Mild Psoriasis - Recent Pipeline Updates 41
Mild Psoriasis - Dormant Projects 43
Mild Psoriasis - Discontinued Products 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Mild Psoriasis, H2 2014 7
Number of Products under Development for Mild Psoriasis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Mild Psoriasis - Pipeline by Avexxin AS, H2 2014 13
Mild Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2014 14
Mild Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2014 15
Mild Psoriasis - Pipeline by GlycoMar Limited, H2 2014 16
Mild Psoriasis - Pipeline by OPKO Health, Inc., H2 2014 17
Mild Psoriasis - Pipeline by Soligenix, Inc., H2 2014 18
Mild Psoriasis - Pipeline by UCB S.A., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Mild Psoriasis Therapeutics - Recent Pipeline Updates, H2 2014 41
Mild Psoriasis - Dormant Projects, H2 2014 43
Mild Psoriasis - Discontinued Products, H2 2014 44